<DOC>
	<DOCNO>NCT01695044</DOCNO>
	<brief_summary>PSMA ADC 2301 Phase 2 , open-label , study assess anti-tumor activity tolerability Prostate Specific Membrane Antigen Antibody Drug Conjugate ( PSMA ADC ) two group subject metastatic castration-resistant prostate cancer ( mCRPC ) . One group comprise subject must receive least one taxane-containing chemotherapy regimen ( e.g . docetaxel , cabazitaxel ) . The second group comprise subject cytotoxic chemotherapy-naïve . Subjects cytotoxic chemotherapy-naïve must receive progressed on- , ineligible , refuse , intolerance to- , access Radium-223 . Both group subject must also receive progressed abiraterone acetate and/or enzalutamide . If subject unable receive abiraterone acetate and/or enzalutamide , Sponsor approval require participation study . Subjects receive eight dos PSMA ADC approximately every three week .</brief_summary>
	<brief_title>A Study PSMA ADC Subjects With Metastatic Castration-resistant Prostate Cancer ( mCRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . A diagnosis metastatic castrationresistant prostate cancer . 2. ) Prior history treatment least one taxanecontaining chemotherapy regimen ( e.g . docetaxel , cabazitaxel ) . If subject receive two cytotoxic chemotherapy regimen , Sponsor approval require study participation . OR b ) No prior history treatment cytotoxic chemotherapy regimen . 3 . Must receive progressed abiraterone acetate and/or enzalutamide . If subject unable receive abiraterone acetate and/or enzalutamide , Sponsor approval require participation study . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . 5 . Life expectancy ≥ six month . 6 . Cytotoxic chemotherapynaïve subject ONLY must receive progressed , ineligible , refuse , intolerance , access Radium223 . 1 . Treatment within 30 day prior first dose study drug follow : External Radiation therapy Radiopharmaceuticals Cytotoxic chemotherapy Treatment investigational agent 2 . Clinically significant cardiac disease severe debilitate pulmonary disease 3 . An acute infection require ongoing antibiotic therapy 4 . Any prior treatment PSMA ADC therapy target PSMA , antibody drug conjugate ( ADC ) product contain monomethyl auristatin E ( MMAE ) ( e.g. , brentuximab vedotin , glembatumumab vedotin , ASG5ME , RG7450 ) unless approve Sponsor . 5 . History drug and/or alcohol abuse 6 . History pancreatitis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>